课题基金 / 基金详情

Comparison of Bivalent vs Pentavalent Subtype C Envelope HIV-1 Vaccine Efficacy Following Mucosal Virus Challenge

Comparison of Bivalent vs Pentavalent Subtype C Envelope HIV-1 Vaccine Efficacy Following Mucosal Virus Challenge
粘膜病毒攻击后二价与五价 C 亚型包膜 HIV-1 疫苗功效的比较
批准号:
10004542
负责人:
RANAJIT PAL
金额:
$15.52万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-08-15 至 2021-03-20

项目摘要

项目成果

RANAJIT PAL的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The development of HIV vaccines and other prevention strategies relies on the use of nonhuman primates in preclinical studies to advance the development of effective AIDS vaccine candidates and to advance development of effective topical microbicides and other prevention modalities or immune-based therapies. The NIAID Simian Vaccine Evaluation Unit (SVEU) contracts shall provide nonhuman primate resources that primarily support preclinical evaluation of AIDS vaccines. The SVEUs conduct studies in support of vaccines being developed by a wide range of investigators. These studies complement NIAID-supported basic vaccine research and vaccine evaluation studies funded through R01 (investigator-initiated research) grants, HIVRAD (HIV Vaccine Research and Design Program) grants, IPCAVD (Integrated Preclinical-Clinical AIDS Vaccine Development) grants, and NHP Consortium awards. The SVEUs also perform studies of candidate vaccines offered by companies or other researchers.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Comprehensive Resources for HIV Microbicides and Biomedical Prevention: NHP Purchase and Holding
Statistical Support for HIV Non-vaccine Biomedical Prevention Product Development
Comprehensive Resources for HIV Microbicides and Biomedical Prevention: Quality Assurance/ Quality Control (QA/QC)
海外基金